4 g/L) and pentane-1-sulfonic acid sodium salt (0.4 g/L) adjusted to pH 3.0 with orthophosphoric acid and acetonitrile as mobile phase B. The gradient program T (min) = % B: 0 = 10, 2 = 15, 5 = 17, 7 = 20, 8 = 25, 9 = 30, 13 = 25, 15 = 10, and 18 = 10, with flow rate of 1.2 mL/min was employed. The injection volume was 10 μL while the detector was set at 273 nm. The column temperature was maintained at 35 °C. About 3.4 g of monobasic sodium phosphate dissolved in 800 mL of water, adjusted to pH 3.5 ± 0.05 with dilute

orthophosphoric acid solution was used as buffer. The diluent used was a mixture of buffer, acetonitrile and water in the ratio of 80:15:5 (v/v/v). A stock solution of Metoclopramide Hydrochloride (240 μg/mL) was prepared by dissolving an appropriate amount in the diluent. Standard Regorafenib solution containing 6 μg/mL was prepared from this stock solution. 5 mL of Metoclopramide injection USP solution containing 5000 μg/mL was dissolved in 25 mL of diluent to give a solution containing 1000 μg/mL as sample solution. The study was intended to ensure the separation of Metoclopramide and its degradation impurities. Forced degradation study was performed to evaluate the stability indicating properties Cobimetinib research buy and specificity of the method. Multiple stressed samples were prepared

as indicated below. Solution containing 1 mg/mL of Metoclopramide was treated with 1 N HCl, 1 N NaOH and water respectively. These samples were refluxed at 80 °C for 5 h. After cooling the solutions were neutralized and diluted with diluent. Solution containing 1 mg/mL of Metoclopramide was treated with 6% w/v H2O2 at 40 °C for 6 h was cooled

and diluted with diluent. The drug solution (5 mg/mL) was subjected to heat at 105 °C for 24 h. After cooling 5 mL of the above solution was transferred in a 25 mL volumetric flask, diluted to the volume with diluent. The drug solution (5 mg/mL) was exposed to the UV light in the photolytic chamber PDK4 providing an overall illumination of 1.2 million lux h and ultraviolet energy of 200 W h/square meters for 184 h. 5 mL of the above solution was transferred in 25 mL volumetric flask, diluted to the volume with diluent. Metoclopramide injection USP (5 mg/mL) was subjected to 25 °C/90% RH for 7 days. 5 mL of the above solution was transferred in 25 mL volumetric flask, diluted to the volume with diluent. The development of selective method for determination of Metoclopramide and its related substances is described as an important issue in method development. Metoclopramide and its related substances show different affinities for chromatographic stationary and mobile phases due to differences in their molecular structures. To obtain a good resolution among the impurities and main drug substance different stationary phases were tested considering; a. The feature of stationary phase.